Iqvia's Big Win: What's Driving the Clinical Trials Boom? Iqvia's latest earnings report has sent its stock soaring past a key buy point. The company's 8. 7% year over year revenue growth to $4.
368 billion in Q2 exceeded analyst expectations, sparking questions about the underlying drivers of Iqvia's success and the broader trends shaping the healthcare industry.
A Boom in Clinical Trials Iqvia's financial performance is part of a larger trend: clinical trials have been experiencing significant growth in recent years.